US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
EP0307434B2
(fr)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Anticorps alteres
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
WO1989006692A1
(fr)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
US5120525A
(en)
|
1988-03-29 |
1992-06-09 |
Immunomedics, Inc. |
Radiolabeled antibody cytotoxic therapy of cancer
|
CA1329119C
(fr)
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Therapie faisant appel a des agents cytotoxiques
|
US20030232010A2
(en)
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
DE69232706T2
(de)
|
1991-05-01 |
2002-11-28 |
Jackson H M Found Military Med |
Verfahren zur behandlung infektiöser respiratorischer erkrankungen
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
DE69216509T2
(de)
|
1991-08-12 |
1997-05-28 |
Takeda Chemical Industries Ltd |
Kondensierte Pyrimidinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
EP0640094A1
(fr)
|
1992-04-24 |
1995-03-01 |
The Board Of Regents, The University Of Texas System |
Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
|
EP0889052B1
(fr)
|
1992-09-15 |
2009-04-15 |
Ortho Diagnostic Systems Inc. |
Peptides immunoreactifs issus du virus d'epstein-barr
|
US7326535B2
(en)
|
1993-09-15 |
2008-02-05 |
Ortho Diagnostic Systems Inc. |
Immunoreactive peptides from Epstein-Barr virus
|
US7060283B1
(en)
|
1992-09-15 |
2006-06-13 |
Ortho Diagnostic Systems, Inc. |
Immunoreactive peptides from Epstein-Barr virus
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
EP0714409A1
(fr)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Anticorps
|
US5834469A
(en)
|
1994-06-09 |
1998-11-10 |
Smithkline Beecham Corporation |
Endothelin receptor antagonists
|
US5686578A
(en)
|
1994-08-05 |
1997-11-11 |
Immunomedics, Inc. |
Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
|
US6132764A
(en)
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
DK0885002T3
(da)
|
1996-03-04 |
2011-08-22 |
Penn State Res Found |
Materialer og fremgangsmåder til forøgelse af cellulær internalisering
|
WO1997039774A1
(fr)
|
1996-04-23 |
1997-10-30 |
Novopharm Biotech, Inc. |
Anticorps monoclonal specifique a l'antigene associe au melanome et ses procedes d'utilisation
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
EP0954282B1
(fr)
|
1997-01-16 |
2005-01-19 |
Massachusetts Institute Of Technology |
Preparation de particules pour inhalation
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US7541020B2
(en)
|
1997-05-08 |
2009-06-02 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6764840B2
(en)
|
1997-05-08 |
2004-07-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US7063967B2
(en)
|
1997-05-08 |
2006-06-20 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6355257B1
(en)
|
1997-05-08 |
2002-03-12 |
Corixa Corporation |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
US6303347B1
(en)
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
EP1724282B1
(fr)
|
1997-05-21 |
2013-05-15 |
Merck Patent GmbH |
Procédé de production de protéines non-immunogènes
|
CA2293632C
(fr)
|
1997-06-12 |
2011-11-29 |
Research Corporation Technologies, Inc. |
Polypeptides d'anticorps artificiels
|
US6248564B1
(en)
|
1997-08-29 |
2001-06-19 |
Harvard University |
Mutant MHC class I molecules
|
US6238667B1
(en)
|
1997-09-19 |
2001-05-29 |
Heinz Kohler |
Method of affinity cross-linking biologically active immunogenic peptides to antibodies
|
US20030103984A1
(en)
|
1998-05-04 |
2003-06-05 |
Heinz Kohler |
Fusion proteins of biologically active peptides and antibodies
|
US7569674B2
(en)
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US20090075339A1
(en)
|
1997-09-19 |
2009-03-19 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US20040185039A1
(en)
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
US20050033033A1
(en)
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
EP2180007B2
(fr)
|
1998-04-20 |
2017-08-30 |
Roche Glycart AG |
Ingénierie de glycosylation pour anticorps afin d'améliorer la cytotoxicité cellulaire en fonction de l'anticorps
|
JP2002513028A
(ja)
|
1998-04-28 |
2002-05-08 |
ガレニカ ファーマシューティカルズ, インコーポレイテッド |
ポリサッカリド抗原結合体
|
US20090208418A1
(en)
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
CA2336139C
(fr)
|
1998-06-24 |
2008-10-14 |
Advanced Inhalation Research, Inc. |
Grandes particules poreuses emises par un inhalateur
|
WO2000030680A1
(fr)
|
1998-11-23 |
2000-06-02 |
Idec Pharmaceuticals Corporation |
Constructions de proteines chimeres gp39 comprenant un anticorps specifique d'un antigene tumoral
|
HUP0104693A3
(en)
|
1998-12-16 |
2003-12-29 |
Warner Lambert Co |
Treatment of arthritis with mek inhibitors
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
EP2264166B1
(fr)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
|
WO2000068213A1
(fr)
|
1999-05-05 |
2000-11-16 |
Aventis Pharma Limited |
Composes bicycliques substitues
|
EP1210372B1
(fr)
|
1999-07-29 |
2008-01-23 |
Medarex, Inc. |
Anticorps monoclonaux humains diriges contre her2/neu
|
SE9903895D0
(sv)
|
1999-10-28 |
1999-10-28 |
Active Biotech Ab |
Novel compounds
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
DE10024069A1
(de)
|
2000-05-17 |
2001-12-13 |
Gluesenkamp Karl Heinz |
Konjugat auf der Basis einer heterobifunktionalen Brückenverbindung, die mit einem Immunmodulator und einer zellerkennenden Einheit substituiert ist
|
WO2001092339A1
(fr)
|
2000-05-31 |
2001-12-06 |
University Of Virginia Patent Foundation |
Marqueur moleculaire pour mitose
|
EE05450B1
(et)
|
2000-07-19 |
2011-08-15 |
Warner-Lambert Company |
4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
|
JP2008531580A
(ja)
|
2000-12-08 |
2008-08-14 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾因子の標的化送達のための組成物および方法
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20050271663A1
(en)
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
MXPA04003798A
(es)
|
2001-10-25 |
2004-07-30 |
Genentech Inc |
Composiciones de glicoproteina.
|
TW200303759A
(en)
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
AU2002357060A1
(en)
|
2001-12-03 |
2003-06-17 |
Abgenix, Inc. |
Antibody categorization based on binding characteristics
|
IL162734A0
(en)
|
2002-02-01 |
2005-11-20 |
Ariad Gene Therapeutics Inc |
Phosphorus-containing compounds & uses thereof
|
PL221491B1
(pl)
|
2002-03-08 |
2016-04-29 |
Eisai R&D Man Co |
Związki makrocykliczne, środek farmaceutyczny zawierający te związki oraz zastosowanie tych związków
|
US20030185835A1
(en)
|
2002-03-19 |
2003-10-02 |
Braun Ralph P. |
Adjuvant for vaccines
|
US20030190308A1
(en)
|
2002-03-19 |
2003-10-09 |
Braun Ralph P. |
Adjuvant
|
DE60325838D1
(de)
|
2002-03-19 |
2009-03-05 |
Glaxo Group Ltd |
Imidazoquinolinamine als adjuvantien für hiv dna vakzine
|
ATE491471T1
(de)
|
2002-03-19 |
2011-01-15 |
Powderject Res Ltd |
Adjuvantien für dns impstoffe basierend auf imidazochinoline
|
US8153141B2
(en)
|
2002-04-04 |
2012-04-10 |
Coley Pharmaceutical Gmbh |
Immunostimulatory G, U-containing oligoribonucleotides
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
ES2401428T3
(es)
|
2002-04-10 |
2013-04-19 |
Genentech, Inc. |
Variantes de anticuerpos anti-HER2
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
US20090068178A1
(en)
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
KR100485155B1
(ko)
|
2002-05-22 |
2005-04-22 |
주식회사 삼양제넥스 |
효소저항전분을 포함하는 면역활성 증강용 조성물
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2318167T3
(es)
|
2002-07-15 |
2009-05-01 |
The Trustees Of Princeton University |
Compuestos de union a iap.
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
AU2003299863B2
(en)
|
2002-08-15 |
2009-09-24 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
WO2004038002A2
(fr)
|
2002-10-25 |
2004-05-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulation de fonction de cellule dendritique et d'autres reponses cellulaires mediees par des compositions de defensine
|
JP4511943B2
(ja)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Pd−1に対する抗体およびその使用
|
EP2368578A1
(fr)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
AU2004213749B2
(en)
|
2003-01-31 |
2010-02-25 |
Celldex Therapeutics, Inc. |
Antibody vaccine conjugates and uses therefor
|
JP2006517974A
(ja)
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトル様受容体8に関する方法および組成物
|
WO2004078146A2
(fr)
|
2003-03-05 |
2004-09-16 |
Innexus Biotechnology International Limited |
Inhibition d'apoptose induite par un anticorps tansmembranaire
|
AU2004252409A1
(en)
|
2003-04-10 |
2005-01-06 |
3M Innovative Properties Company |
Methods and compositions for enhancing immune response
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
EP1617871A4
(fr)
|
2003-04-10 |
2010-10-06 |
3M Innovative Properties Co |
Distribution de composes modifiant une reponse immunitaire au moyen de materiaux de support particulaires contenant du metal
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
US7462403B2
(en)
|
2003-06-27 |
2008-12-09 |
Tdk Corporation |
R-T-B system permanent magnet
|
WO2005018555A2
(fr)
|
2003-08-14 |
2005-03-03 |
3M Innovative Properties Company |
Modificateurs de la reponse immunitaire a modification lipidique
|
JP2007503268A
(ja)
|
2003-08-25 |
2007-02-22 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾化合物の送達
|
US20050048072A1
(en)
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
WO2005033049A2
(fr)
|
2003-10-01 |
2005-04-14 |
Taro Pharmaceuticals U.S.A., Inc. |
Procede de preparation de 4-amino-1h-imidazo(4,5-c)quinolines et sels d'ajout acides de celles-ci
|
US20050239733A1
(en)
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
US20050175630A1
(en)
|
2003-12-23 |
2005-08-11 |
Eyal Raz |
Immunogenic compositions and methods of use thereof
|
JP2007528838A
(ja)
|
2003-12-24 |
2007-10-18 |
ライデン ユニバーシティ メディカル センター |
腫瘍特異的ワクチンとしての合成タンパク質
|
JP2007523061A
(ja)
|
2004-01-16 |
2007-08-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Smacペプチドミメティクスおよびその使用法
|
MXPA06008095A
(es)
|
2004-01-16 |
2007-03-28 |
Univ Michigan |
Mimeticos de smac conformacionalmente restringidos y sus usos.
|
WO2005070959A2
(fr)
|
2004-01-23 |
2005-08-04 |
Vievax Corp. |
Compositions renfermant des agents de modification de reponse immunitaire et procedes d'utilisation
|
CA2553785C
(fr)
|
2004-02-14 |
2011-02-08 |
Irm Llc |
Composes et compositions tenant lieu d'inhibiteurs de la proteine kinase
|
EP1740173A4
(fr)
|
2004-03-23 |
2009-05-27 |
Genentech Inc |
Inhibiteurs azabicyclo-octane de l'iap
|
EP2253614B1
(fr)
|
2004-04-07 |
2012-09-19 |
Novartis AG |
Inhibiteurs de IAP
|
CA2562283A1
(fr)
|
2004-04-09 |
2005-11-24 |
3M Innovative Properties Company |
Methodes, compositions et preparations pour administration de modificateurs de reponse immunitaire (irm)
|
WO2005107760A1
(fr)
|
2004-04-30 |
2005-11-17 |
Irm Llc |
Composes et compositions en tant qu'inducteurs de la differenciation de keratinocytes
|
NZ551938A
(en)
|
2004-06-02 |
2010-07-30 |
Takeda Pharmaceutical |
Fused heterocyclic compound
|
WO2006080946A2
(fr)
|
2004-06-08 |
2006-08-03 |
Coley Pharmaceutical Gmbh |
Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
|
ES2524449T3
(es)
|
2004-07-02 |
2014-12-09 |
Genentech, Inc. |
Inhibidores de IAP
|
WO2006010118A2
(fr)
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Mimetiques de smac contraints par conformation et utilisations de ceux-ci
|
MX2007000490A
(es)
|
2004-07-12 |
2007-06-11 |
Idun Pharmaceuticals Inc |
Analogos de tetrapeptido.
|
EP1773766B1
(fr)
|
2004-07-15 |
2014-04-02 |
Tetralogic Pharmaceuticals Corporation |
Composes de liaison aux proteines iap
|
WO2006134423A2
(fr)
|
2004-07-18 |
2006-12-21 |
Coley Pharmaceutical Group, Ltd. |
Methodes et compositions utiles pour induire des reponses immunitaires innees
|
BRPI0513681A
(pt)
|
2004-07-22 |
2008-05-13 |
Genentech Inc |
composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer
|
WO2006026394A2
(fr)
|
2004-08-27 |
2006-03-09 |
3M Innovative Properties Company |
Procédé pour provoquer une réponse immunitaire contre le hiv
|
US7521541B2
(en)
|
2004-09-23 |
2009-04-21 |
Genetech Inc. |
Cysteine engineered antibodies and conjugates
|
MX2007003320A
(es)
|
2004-09-24 |
2007-05-18 |
Amgen Inc |
Moleculas fc modificadas.
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US20060135459A1
(en)
|
2004-11-09 |
2006-06-22 |
Epstein Alan L |
Targeted innate immunity
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
CN101146803A
(zh)
|
2004-12-20 |
2008-03-19 |
健泰科生物技术公司 |
Iap的吡咯烷抑制剂
|
RU2383545C2
(ru)
|
2005-03-15 |
2010-03-10 |
Айрм Ллк |
Соединения и композиции в качестве ингибиторов протеинкиназы
|
WO2006116423A2
(fr)
|
2005-04-26 |
2006-11-02 |
Eisai Co., Ltd |
Compositions et procedes destines a l'immunotherapie du cancer
|
KR101339628B1
(ko)
|
2005-05-09 |
2013-12-09 |
메다렉스, 인코포레이티드 |
예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
NZ564592A
(en)
|
2005-07-01 |
2011-11-25 |
Medarex Inc |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
CA2618218C
(fr)
|
2005-07-21 |
2015-06-30 |
Ardea Biosciences, Inc. |
Inhibiteurs n-(arylamino)-sulfonamide de mek
|
WO2008020827A2
(fr)
|
2005-08-01 |
2008-02-21 |
Biogen Idec Ma Inc. |
Polypeptides modifiés, immunoconjugués de ceux-ci et procédés apparentés
|
PT2573114T
(pt)
|
2005-08-10 |
2016-07-13 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
JP2009521218A
(ja)
|
2005-12-20 |
2009-06-04 |
イデラ ファーマシューティカルズ インコーポレイテッド |
異なる長さのパリンドロームセグメントを含むパリンドローム免疫調節オリゴヌクレオチド(imo(tm))の免疫賦活作用
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
EP3085373A1
(fr)
|
2006-02-22 |
2016-10-26 |
3M Innovative Properties Company |
Conjugués de modificateur de réponse immunitaire
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
US20090074711A1
(en)
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
LT2845866T
(lt)
|
2006-10-27 |
2017-07-10 |
Genentech, Inc. |
Antikūnai ir imunokonjugatai bei jų panaudojimas
|
WO2008140603A2
(fr)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
|
NZ598890A
(en)
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
CA2691357C
(fr)
|
2007-06-18 |
2014-09-23 |
N.V. Organon |
Anticorps diriges contre le recepteur humain de mort programmee pd-1
|
WO2009002939A2
(fr)
|
2007-06-23 |
2008-12-31 |
Innexus Biotechnology International Limited |
Anticorps autophiles
|
KR101584823B1
(ko)
|
2007-09-12 |
2016-01-22 |
제넨테크, 인크. |
포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
|
MY188455A
(en)
|
2007-10-19 |
2021-12-09 |
Genentech Inc |
Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
MX2010005783A
(es)
|
2007-11-27 |
2010-08-10 |
Ablynx Nv |
Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
|
US9358307B2
(en)
|
2008-01-25 |
2016-06-07 |
Gavish-Galilee Bio Applications Ltd. |
Targeting of innate immune response to tumor site
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
CA2714177A1
(fr)
|
2008-02-06 |
2009-08-13 |
Novartis Ag |
Composes heterocycliques
|
WO2009101611A1
(fr)
|
2008-02-11 |
2009-08-20 |
Curetech Ltd. |
Anticorps monoclonaux pour le traitement de tumeurs
|
WO2009114335A2
(fr)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Protéines de liaison avec pd-1
|
CA2720368C
(fr)
|
2008-04-02 |
2017-08-22 |
Macrogenics, Inc. |
Anticorps specifiques de her2/neu et procedes d'utilisation de ceux-ci
|
EP2383292A1
(fr)
*
|
2008-05-02 |
2011-11-02 |
Novartis AG |
Molécules de liaison améliorées à base de fibronectine et utilisations associées
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
EP2328920A2
(fr)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Polypeptides co-stimulateurs ciblés et leurs procédés d'utilisation dans le traitement du cancer
|
WO2010048149A2
(fr)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
|
CN104479018B
(zh)
|
2008-12-09 |
2018-09-21 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
AR074760A1
(es)
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
EP3192811A1
(fr)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Anticorps pd-1 et pd-l1 et leurs utilisations
|
RU2012101999A
(ru)
|
2009-06-22 |
2013-07-27 |
МЕДИММЬЮН, ЭлЭлСи |
РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
|
EP2451838A1
(fr)
|
2009-07-09 |
2012-05-16 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Domaines constants d une immunoglobuline stabilisée
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス,インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
EP2504028A4
(fr)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
Inhibition simultanée de pd-l1/pd-l2
|
ES2527143T3
(es)
|
2009-12-07 |
2015-01-20 |
Fundació Privada Institució Catalana De Recerca I Estudis Avançants |
Anticuerpos frente a variante truncada CTF-611 de HER2
|
EP2513148B1
(fr)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anticorps anti-her2 et leurs utilisations
|
CN102167742B
(zh)
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
EP2558501B1
(fr)
|
2010-04-15 |
2016-09-07 |
Alper Biotech, Llc |
Anticorps monoclonaux contre antigènes her2 et leurs utilisations
|
WO2011140338A1
(fr)
|
2010-05-05 |
2011-11-10 |
Gatekeeper Pharmaceuticals, Inc. |
Composés modulant l'activité des récepteurs egfr et méthodes pour traiter ou prévenir des troubles à l'aide de ceux-ci
|
JP2013166700A
(ja)
|
2010-06-02 |
2013-08-29 |
Dainippon Sumitomo Pharma Co Ltd |
新規4,5−縮環ピリミジン誘導体
|
SG10201600791TA
(en)
|
2010-06-08 |
2016-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
LT2585470T
(lt)
|
2010-06-23 |
2017-04-10 |
Hanmi Science Co., Ltd. |
Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui
|
JP2013535508A
(ja)
|
2010-08-13 |
2013-09-12 |
ベイラー リサーチ インスティテュート |
抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
|
US20120321694A1
(en)
|
2010-10-27 |
2012-12-20 |
Daniel Larocque |
Compositions and uses
|
TW201247706A
(en)
*
|
2011-03-08 |
2012-12-01 |
Baylor Res Inst |
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2570125A1
(fr)
|
2011-09-16 |
2013-03-20 |
Almirall, S.A. |
Ligands du récepteur Ep1
|
EP3539982A3
(fr)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
|
WO2013179174A1
(fr)
|
2012-05-29 |
2013-12-05 |
Koninklijke Philips N.V. |
Système d'éclairage
|
US20150104468A1
(en)
|
2012-06-04 |
2015-04-16 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
PT2906563T
(pt)
*
|
2012-10-10 |
2018-05-23 |
Janssen Sciences Ireland Uc |
Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
|
WO2014083505A1
(fr)
*
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Procédés pour la fabrication de conjugués à partir de protéines contenant du disulfure
|
MX2015010146A
(es)
*
|
2013-02-08 |
2016-05-31 |
Novartis Ag |
Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
|
WO2014124258A2
(fr)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
|
TW201446792A
(zh)
|
2013-03-12 |
2014-12-16 |
Amgen Inc |
Nav1.7之強效及選擇性抑制劑
|
CN105007950B
(zh)
*
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
WO2014151030A1
(fr)
|
2013-03-15 |
2014-09-25 |
Novartis Ag |
Inhibiteurs de la prolifération cellulaire et leurs conjugués
|
MY175308A
(en)
|
2013-05-18 |
2020-06-18 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
US10385054B2
(en)
|
2013-06-27 |
2019-08-20 |
Janssen Sciences Ireland Unlimited Company |
Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
|
KR20160088429A
(ko)
|
2013-11-26 |
2016-07-25 |
노파르티스 아게 |
케톤-변형된 폴리펩티드에 대한 옥심 접합을 위한 방법
|
JP2017502068A
(ja)
|
2014-01-10 |
2017-01-19 |
シャンハイ バーディー バイオテック インコーポレイテッド |
Her2陽性腫瘍を処置するための化合物及び組成物
|
CN106170299A
(zh)
*
|
2014-01-22 |
2016-11-30 |
小利兰斯坦福大学托管委员会 |
用于抗体和抗体负载树突状细胞介导治疗的方法和组合物
|
MX2016011627A
(es)
|
2014-03-12 |
2016-11-29 |
Novartis Ag |
Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados.
|
CN107001354B
(zh)
|
2014-04-11 |
2021-06-22 |
台北医学大学 |
组蛋白去乙酰酶抑制剂
|
SG11201608299TA
(en)
*
|
2014-05-01 |
2016-11-29 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists
|
PL3137470T3
(pl)
|
2014-05-01 |
2021-10-11 |
Novartis Ag |
Związki i kompozycje jako agonisty receptora toll-like 7
|
KR20170016479A
(ko)
|
2014-06-13 |
2017-02-13 |
노파르티스 아게 |
아우리스타틴 유도체 및 그의 접합체
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
EP4001311A1
(fr)
|
2014-07-09 |
2022-05-25 |
Birdie Biopharmaceuticals Inc. |
Combinaisons anti-pd-l1 pour le traitement des tumeurs
|
WO2016011422A2
(fr)
|
2014-07-17 |
2016-01-21 |
Czerniecki Brian J |
Fabrication de vaccins à base de cellules dendritiques multi-doses prêts à être injectés, et polythérapie pour bloquer her2 et her3
|
JP6967963B2
(ja)
|
2014-07-17 |
2021-11-17 |
ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. |
複数用量注射準備済樹状細胞ワクチンの製造ならびにher2およびher3を遮断するための併用療法
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
JP6698084B2
(ja)
|
2014-08-08 |
2020-05-27 |
オンコクエスト インコーポレイテッドOncoquest Inc. |
がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびtlr3刺激
|
DK3190113T3
(da)
|
2014-08-15 |
2021-06-07 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于***的抗-pd-l1结合物
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
EP3215519A1
(fr)
|
2014-11-06 |
2017-09-13 |
Novartis AG |
Dérivés d'amatoxine et leurs conjugués comme inhibiteurs de l'arn polymérase
|
CN104650228B
(zh)
|
2014-11-26 |
2017-11-28 |
嘉和生物药业有限公司 |
一种全人源her2抗体、其编码基因及应用
|
AU2015359692B2
(en)
|
2014-12-08 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
|
CA3081058C
(fr)
|
2015-01-16 |
2024-02-20 |
Academia Sinica |
Unites de lieurs et utilisations dans la configuration de molecules pharmaceutiques
|
CN107847588B
(zh)
|
2015-05-20 |
2021-12-28 |
免疫功坊股份有限公司 |
具有靶向部分及效应部分的分子构建体及其应用
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
CN115300640A
(zh)
|
2015-08-10 |
2022-11-08 |
杭州多禧生物科技有限公司 |
新型连接体及其用于药物和生物分子的特异性偶联
|
MX2018002319A
(es)
|
2015-08-24 |
2018-04-11 |
Glaxosmithkline Ip No 2 Ltd |
Composiciones biofarmaceuticas.
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
MX2018005708A
(es)
|
2015-11-05 |
2018-11-09 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
|
CA3013412C
(fr)
|
2016-02-04 |
2023-10-10 |
Suzhou M-Conj Biotech Co., Ltd. |
Lieurs de conjugaison specifique, immunoconjugues specifiques de ceux-ci, procedes de fabrication et utilisations desdits conjugues de ceux-ci
|
CN107043379A
(zh)
|
2016-02-05 |
2017-08-15 |
正大天晴药业集团股份有限公司 |
一种tlr7激动剂的晶型a、其制备方法和医药用途
|